Dmitri Wiederschain

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Single-vector inducible lentiviral RNAi system for oncology target validation
    Dmitri Wiederschain
    Oncology Research, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA
    Cell Cycle 8:498-504. 2009
  2. ncbi PTEN-deficient cancers depend on PIK3CB
    Susan Wee
    Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 105:13057-62. 2008
  3. ncbi The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells
    Zainab Jagani
    Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
    Cancer Res 70:5528-38. 2010
  4. ncbi Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis
    Dmitri Wiederschain
    Oncology Research, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Mol Cell Biol 27:4968-79. 2007
  5. ncbi Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development
    Susan Wee
    Novartis Institute for Biomedical Research, Cambridge, Massachusetts 02319, USA
    Curr Opin Oncol 20:77-82. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Single-vector inducible lentiviral RNAi system for oncology target validation
    Dmitri Wiederschain
    Oncology Research, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA
    Cell Cycle 8:498-504. 2009
    ..The versatile and robust inducible lentiviral RNAi system reported herein can therefore serve as a powerful tool to rapidly reveal tumor cell dependence...
  2. ncbi PTEN-deficient cancers depend on PIK3CB
    Susan Wee
    Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 105:13057-62. 2008
    ..This unexpected finding demonstrates the need to tailor therapeutic approaches to the genetic basis of PI3K pathway activation to achieve optimal treatment response...
  3. ncbi The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells
    Zainab Jagani
    Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
    Cancer Res 70:5528-38. 2010
    ..Therefore, these studies not only highlight Bmi-1 as a cancer-dependent factor in multiple myeloma, but also elucidate a novel antiapoptotic mechanism for Bmi-1 function involving the suppression of Bim...
  4. ncbi Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis
    Dmitri Wiederschain
    Oncology Research, Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
    Mol Cell Biol 27:4968-79. 2007
    ..Taken together, these results suggest that Bmi-1 and Mel-18 may have overlapping functions in cancer cell growth...
  5. ncbi Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development
    Susan Wee
    Novartis Institute for Biomedical Research, Cambridge, Massachusetts 02319, USA
    Curr Opin Oncol 20:77-82. 2008
    ..This review summarizes the current knowledge about specific contributions of Class IA phosphoinositide 3-kinases to tumorigenesis and presents a rationale for the development of isoform-specific inhibitors...